Application of Multi-Criteria Decision Analysis (mcda) Scoring As an Hta Methodology for Off-Patent Pharmaceuticals (opp) in Emerging Markets

D. Brixner,N. Maniadakis,Z. Kalo,S. Hu,A. Johnston,J. Shen,K. E. Wijaya

DOI: https://doi.org/10.1016/j.jval.2016.08.663

IF: 5.156

2016-01-01

Value in Health

Abstract:HTA has not generally been applied to off-patent pharmaceuticals. MCDA simple scoring has been emerging as a useful HTA approach, which may be applied to evaluate off-patent pharmaceuticals, which treat a majority of patient populations in emerging markets and play a vital role in achieving universal coverage for these countries. Twenty-two criteria were identified through a review of the literature and WHO, FDA, and EU procurement directives and categorized into four categories: product, manufacturer, service and economics. These criteria were presented, discussed, and ranked from five (significantly important) to zero (not important) with fifty-seven healthcare experts and decision makers across emerging markets at the International Society of Pharmacoeconomics and Outcome Research (ISPOR) Annual Meeting in Milan, 9th November 2015. An audience response system was used to collect the data for each category. Drug safety, manufacturing site quality certification and quality assurance of API & production process were the top three criteria across all categories. In the product category level, Bio-Equivalence (BE), level of interchangeability, and Pharmaceutical Equivalence (PE) were the top three criteria. In the manufacturer category, manufacturing site quality certification, quality assurances of API & production process and supply track record were the top three criteria. In the service category pharmacovigilance, local investment and distribution practices were the top three criteria. Finally, in the economic category, drug safety, clinical efficacy & efficacy and direct cost were the top three criteria. MCDA scoring can be deployed as a HTA methodology to evaluate off-patent pharmaceuticals. This method can assist to develop evidence-based criteria for MCDA and engage appropriate stakeholders from emerging markets to support transparent decision-making. The presented criteria for MCDA are flexible and can be tailored based on healthcare priorities and stages.